Cryoport (CYRX) CFO sells 41,443 shares and receives fresh stock grants

Rhea-AI Filing Summary

Cryoport, Inc. Chief Financial Officer Robert Stefanovich reported a mix of equity compensation grants, option exercises, and tax-driven share sales. He exercised options for 87,188 shares of Common Stock at $1.87 per share and sold 38,700 shares on the same day at a weighted average price of $7.7619. According to the footnotes, the sale proceeds were used to pay the option exercise price and related withholding taxes, making this largely a liquidity and tax event rather than a pure discretionary sale.

On a later date, he sold an additional 2,743 shares at $8.00 per share, which the company’s policies required to cover taxes due on vesting restricted stock rights. He also received 27,413 restricted stock rights that will vest in four equal annual installments beginning March 14, 2027, and a stock option grant for 82,240 shares at an exercise price of $8.60 per share, expiring in 2033. After these transactions, Stefanovich directly holds 280,371 shares of Cryoport common stock, so the 41,443 shares sold represent a minority portion of his overall equity position.

Insider Trade Summary

Net Seller: 41,443 shares ($322,330)

Net Sell 6 txns

Insider STEFANOVICH ROBERT

Role Chief Financial Officer

Sold 41,443 shs ($322K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,743	$8.00	$22K
Grant/Award	Stock Option (right to buy)	82,240	$0.00	--
Grant/Award	Common Stock	27,413	$0.00	--
Exercise	Options to purchase common stock	87,188	$0.00	--
Exercise	Common Stock	87,188	$1.87	$163K
Sale	Common Stock	38,700	$7.7619	$300K

Holdings After Transaction: Common Stock — 280,371 shares (Direct); Stock Option (right to buy) — 82,240 shares (Direct); Options to purchase common stock — 0 shares (Direct)

Footnotes (1)

1. The proceeds of the sale of Common Stock were used to pay the exercise price and withholding taxes due upon exercise of the Stock Option reported in this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.725 to $7.83, inclusive. Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2027. Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. 1/48 of options vested on the 6th of each month for forty-eight months beginning May 6, 2016. 1/48 of options vest on the 14th of each month for forty-eight months beginning April 14, 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STEFANOVICH ROBERT

(Last) (First) (Middle)

C/O CRYOPORT INC.

112 WESTWOOD PLACE, SUITE 350

(Street)

BRENTWOOD TN 37027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cryoport, Inc. [ CYRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		M		87,188	A	$1.87	294,401	D
Common Stock	03/12/2026		S(1)		38,700	D	$7.7619(2)	255,701	D
Common Stock(3)	03/14/2026		A		27,413	A	$0(3)	283,114	D
Common Stock	03/16/2026		S(4)		2,743	D	$8	280,371	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to purchase common stock	$1.87	03/12/2026		M			87,188	(5)	05/06/2026	Common Stock	87,188	$0	0	D
Stock Option (right to buy)	$8.6	03/14/2026		A		82,240		(6)	03/14/2033	Common Stock	82,240	$0	82,240	D

Explanation of Responses:

1. The proceeds of the sale of Common Stock were used to pay the exercise price and withholding taxes due upon exercise of the Stock Option reported in this Form 4.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.725 to $7.83, inclusive.

3. Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2027.

4. Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.

5. 1/48 of options vested on the 6th of each month for forty-eight months beginning May 6, 2016.

6. 1/48 of options vest on the 14th of each month for forty-eight months beginning April 14, 2026.

Remarks:

With respect to prices reported as weighted average prices in Table I, the reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the applicable footnotes to this Form 4.

	/s/ Robert Stefanovich	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Cryoport (CYRX) CFO Robert Stefanovich report?

Cryoport CFO Robert Stefanovich reported exercising options for 87,188 shares, receiving new stock option and restricted stock grants, and selling 41,443 shares. The sales mainly funded option exercise costs and taxes tied to equity compensation, rather than representing a full discretionary share reduction.

How many Cryoport (CYRX) shares did the CFO sell and at what prices?

Robert Stefanovich sold 38,700 Cryoport shares at a weighted average price of $7.7619 and another 2,743 shares at $8.00. Footnotes explain these sales funded the option exercise price and withholding taxes associated with stock option exercises and restricted stock vesting.

How many Cryoport (CYRX) shares does the CFO own after these transactions?

After the reported transactions, Cryoport CFO Robert Stefanovich directly holds 280,371 shares of common stock. This means the 41,443 shares sold represent a minority of his total stake, leaving him with a substantial ongoing equity position in the company.

What new equity awards did the Cryoport (CYRX) CFO receive?

Robert Stefanovich received 27,413 restricted stock rights and a stock option grant for 82,240 shares at an $8.60 exercise price. The restricted stock rights vest in four equal annual installments starting March 14, 2027, while the options expire in 2033 under a long-term vesting schedule.

Were the Cryoport (CYRX) CFO’s share sales routine tax-related transactions?

Footnotes indicate the share sales were largely tax and exercise related. Proceeds from the 38,700-share sale paid the option exercise price and withholding taxes, while 2,743 shares were required to be sold under company policies to cover taxes on vesting restricted stock rights.

What was the significance of the option exercise by Cryoport (CYRX) CFO?

The CFO exercised options to acquire 87,188 shares at $1.87 per share, converting a derivative position into common stock. This was paired with sales mainly to cover costs and taxes, and he retained a sizable direct holding afterward, indicating continued exposure to Cryoport’s equity.